JP2010540454A - ピマバンセリンと他の薬剤との併用投与 - Google Patents

ピマバンセリンと他の薬剤との併用投与 Download PDF

Info

Publication number
JP2010540454A
JP2010540454A JP2010526035A JP2010526035A JP2010540454A JP 2010540454 A JP2010540454 A JP 2010540454A JP 2010526035 A JP2010526035 A JP 2010526035A JP 2010526035 A JP2010526035 A JP 2010526035A JP 2010540454 A JP2010540454 A JP 2010540454A
Authority
JP
Japan
Prior art keywords
disease
composition
pimavanserin
disorder
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010526035A
Other languages
English (en)
Japanese (ja)
Inventor
ハックセル，ウリ
マクファーランド，クリスタ
Original Assignee
アカディア ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アカディア ファーマシューティカルズ，インコーポレーテッド filed Critical アカディア ファーマシューティカルズ，インコーポレーテッド
Publication of JP2010540454A publication Critical patent/JP2010540454A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010526035A 2007-09-21 2008-09-19 ピマバンセリンと他の薬剤との併用投与 Withdrawn JP2010540454A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97442607P 2007-09-21 2007-09-21
US98625007P 2007-11-07 2007-11-07
US5097608P 2008-05-06 2008-05-06
PCT/US2008/077139 WO2009039460A2 (en) 2007-09-21 2008-09-19 Co-administration of pimavanserin with other agents

Publications (1)

Publication Number Publication Date
JP2010540454A true JP2010540454A (ja) 2010-12-24

Family

ID=40350231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010526035A Withdrawn JP2010540454A (ja) 2007-09-21 2008-09-19 ピマバンセリンと他の薬剤との併用投与

Country Status (10)

Country Link
US (2) US20090082388A1 (enExample)
EP (1) EP2200610B1 (enExample)
JP (1) JP2010540454A (enExample)
AU (1) AU2008302079A1 (enExample)
CA (1) CA2700331A1 (enExample)
DK (1) DK2200610T3 (enExample)
HU (1) HUE037639T2 (enExample)
NO (1) NO2200610T3 (enExample)
SI (1) SI2200610T1 (enExample)
WO (1) WO2009039460A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518543A (ja) * 2011-02-25 2014-07-31 ヘルシン ヘルスケア ソシエテ アノニム 不斉尿素及びその医学的用途
JP2017507116A (ja) * 2014-03-07 2017-03-16 ヘルシン ヘルスケア ソシエテ アノニム ｐ−置換非対称尿素及びその医薬的使用
US10501479B2 (en) 2016-03-22 2019-12-10 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
JP2020531505A (ja) * 2017-08-21 2020-11-05 アカディア ファーマシューティカルズ インコーポレーテッド 疾患の治療のための化合物、その塩、及び方法

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
SMT201800199T1 (it) 2008-10-28 2018-05-02 Arena Pharm Inc Composizioni di un modulatore dei recettori della serotonina 5-ht2a utili per il trattamento di disturbi correlati a esso
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011103448A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP3718547A1 (en) * 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US9446037B2 (en) * 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
ES2811088T3 (es) 2014-04-23 2021-03-10 Takeda Pharmaceuticals Co Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
ES2762951T3 (es) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche Nuevo uso terapéutico de la neurotoxina botulínica serotipo A
EP3299016B1 (en) * 2015-05-18 2020-12-16 Chongqing Runze Pharmaceutical Co. Ltd. Use of dextrorotatory oxiracetam in pharmaceutical field
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
US10323027B2 (en) 2015-06-26 2019-06-18 Takeda Pharmaceutical Company Limited 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
TW201720439A (zh) * 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
CN105929030B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种哌马色林中有机杂质的检测方法
CN105481757A (zh) * 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
CN106943345A (zh) * 2016-02-25 2017-07-14 重庆润泽医药有限公司 一种注射用的左旋奥拉西坦及其制备方法
CN106943344B (zh) * 2016-02-25 2018-12-14 重庆润泽医药有限公司 一种稳定性好的(s)-4-羟基-2氧代-1-吡咯烷乙酰胺注射剂及其制备方法
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3436010B1 (en) * 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US20190117636A1 (en) * 2016-03-29 2019-04-25 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN106943361A (zh) * 2016-03-31 2017-07-14 重庆润泽医药有限公司 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺无菌粉末及其制备方法
CN106943360A (zh) * 2016-03-31 2017-07-14 重庆润泽医药有限公司 一种左旋奥拉西坦无菌粉末及其制备方法
CN107303268A (zh) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 稳定抗氧化的左旋奥拉西坦注射液的制备方法
CN107303269A (zh) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 一种左旋奥拉西坦注射液的制备方法
CN107303270A (zh) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 一种稳定抗氧化的(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺注射液
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
MX391629B (es) 2018-09-28 2025-03-21 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico
WO2020092618A1 (en) * 2018-10-30 2020-05-07 Acadia Pharmaceuticals Inc. Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin
CN109633026A (zh) * 2019-01-03 2019-04-16 上海市农业科学院 一种液相色谱-串联质谱检测多菌灵及其代谢物的方法
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
JP2024507367A (ja) * 2021-02-24 2024-02-19 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための方法
EP4297871A4 (en) * 2021-02-26 2025-01-01 BioXcel Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TREATING AGITATION
WO2022246186A1 (en) * 2021-05-21 2022-11-24 Diana Driscoll Methods and compositions for correction of autonomic dysfunctiions
WO2022265878A1 (en) * 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
WO2024112941A1 (en) * 2022-11-22 2024-05-30 GATC Health Corp Butyrylcholinesterase (buche) lateral flow assay (lfa) for determining elevated risk of sids

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
GB1586468A (en) * 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) * 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) * 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) * 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
EP0871440B1 (en) * 1995-12-07 2006-03-22 Daniel C. Javitt Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
JP2003514763A (ja) * 1998-04-14 2003-04-22 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) * 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US20050148018A1 (en) * 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
PT1263729E (pt) * 2000-03-06 2007-03-30 Acadia Pharm Inc Compostos azacílclicos para utilização no tratamento de doenças relacionadas com a serotonina
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
DE60141752D1 (de) * 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
WO2002076464A1 (en) * 2001-03-22 2002-10-03 Arena Pharmaceuticals, Inc. Anti-psychosis combination
DE60236206D1 (de) * 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BR0312217A (pt) * 2002-06-24 2005-05-10 Acadia Pharm Inc Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
ES2314362T3 (es) * 2003-01-16 2009-03-16 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas.
EP1576985A1 (en) * 2004-03-18 2005-09-21 B&B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
KR101260036B1 (ko) * 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518543A (ja) * 2011-02-25 2014-07-31 ヘルシン ヘルスケア ソシエテ アノニム 不斉尿素及びその医学的用途
US9751836B2 (en) 2011-02-25 2017-09-05 Helsinn Healthcare Sa Asymmetric ureas and medical uses thereof
US10407390B2 (en) 2011-02-25 2019-09-10 Helsinn Healthcare Sa Asymmetric ureas and medical uses thereof
JP2017507116A (ja) * 2014-03-07 2017-03-16 ヘルシン ヘルスケア ソシエテ アノニム ｐ−置換非対称尿素及びその医薬的使用
US10501479B2 (en) 2016-03-22 2019-12-10 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
JP2020531505A (ja) * 2017-08-21 2020-11-05 アカディア ファーマシューティカルズ インコーポレーテッド 疾患の治療のための化合物、その塩、及び方法
JP7297738B2 (ja) 2017-08-21 2023-06-26 アカディア ファーマシューティカルズ インコーポレーテッド 疾患の治療のための化合物、その塩、及び方法
JP2023116691A (ja) * 2017-08-21 2023-08-22 アカディア ファーマシューティカルズ インコーポレーテッド 疾患の治療のための化合物、その塩、及び方法
JP7628578B2 (ja) 2017-08-21 2025-02-10 アカディア ファーマシューティカルズ インコーポレーテッド 疾患の治療のための化合物、その塩、及び方法

Also Published As

Publication number Publication date
DK2200610T3 (en) 2018-04-23
CA2700331A1 (en) 2009-03-26
US20140349976A1 (en) 2014-11-27
EP2200610A2 (en) 2010-06-30
SI2200610T1 (en) 2018-06-29
HUE037639T2 (hu) 2018-09-28
WO2009039460A2 (en) 2009-03-26
US20090082388A1 (en) 2009-03-26
EP2200610B1 (en) 2018-01-10
AU2008302079A1 (en) 2009-03-26
WO2009039460A3 (en) 2009-11-26
NO2200610T3 (enExample) 2018-06-09

Similar Documents

Publication Publication Date Title
JP2010540454A (ja) ピマバンセリンと他の薬剤との併用投与
US20090082342A1 (en) N-substituted piperidine derivatives as serotonin receptor agents
AU2017201536B2 (en) Pyrimidinyl Tyrosine Kinase Inhibitors
ES2227287T3 (es) Compuestos quimicos.
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
EP2882751B1 (en) Deuterated ibrutinib
KR20220092920A (ko) 헬리오스의 소분자 분해제 및 사용 방법
TW201720816A (zh) Ｃｘｃｒ２抑制劑
US20030176693A1 (en) Diphenylalkylamine derivatives useful as opioid receptor agonists
JP5579920B2 (ja) バソプレシンアンタゴニストとしてのアリール−／ヘテロアリール−シクロヘキセニル−テトラアザベンゾ［ｅ］アズレン
CN114042070A (zh) 作为神经元组胺受体-3拮抗剂的化合物及其用途
CA3045816A1 (en) Oga inhibitor compounds
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN104829628B (zh) 八氢噻吩并喹啉衍生物、包含所述衍生物的药物组合物及它们的用途
TWI338687B (enExample)
EP3810593A1 (en) Oga inhibitor compounds
EP3233799B1 (en) Dopamine d2 receptor ligands
JPWO2003035641A1 (ja) 新規カルバモイルピロリドン誘導体
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
TW201831462A (zh) 二苯并二氮呯衍生物
US11780843B2 (en) Compounds active towards nuclear receptors
JP7713954B2 (ja) 核内受容体に対して活性な化合物
TW202430523A (zh) pan-KRAS降解劑及其製備方法與應用

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20111206